An Oral Peptide Pill Kept Psoriasis Clear Through Two Years

Peptides are supposed to fall apart in the stomach. Stomach acid and digestive enzymes chew up most peptide chains before they ever reach the bloodstream, which is why insulin, GLP-1 drugs and nearly every other peptide medicine on the market has to be injected. Johnson & Johnson's icotrokinra breaks that pattern: it's a peptide that blocks the interleukin-23 (IL-23) receptor, swallowed once a day as a 200 mg tablet, and on October 2, 2026 the company reported two-year data showing it held up.

The data come from ICONIC-TOTAL, a phase 3 trial in adults and adolescents (12 and older) with moderate-to-severe plaque psoriasis specifically at sites that are notoriously hard to clear: the scalp, the genitals, the hands and feet. At week 112, 70% of patients on icotrokinra had clear or almost-clear skin overall. Broken out by site: 60% had completely clear scalp skin, 63% completely clear hands and feet, and 89% completely clear genital skin — a site that typically responds worse than the rest of the body, not better. Trade coverage at the European Academy of Dermatology and Venereology Congress put the same figures in context: response rates climbed steadily from week 16 (57% clear/almost-clear) through week 112, with no new safety signals and adverse events — headache, nausea, fungal infection, fatigue — holding steady or declining over time.

Icotrokinra itself isn't new. The FDA approved Johnson & Johnson's icotrokinra in March 2026 for moderate-to-severe plaque psoriasis in patients 12 and up, based on an earlier set of trials (ICONIC-LEAD, ICONIC-ADVANCE 1 and 2, ICONIC-ASCEND) that compared it directly against an injectable biologic and an existing oral drug. What's new is the durability data from the hardest-to-treat subgroup, run out to two full years.

How a peptide survives being swallowed

The engineering problem here isn't the IL-23 receptor — several injectable biologics already block it. It's getting a peptide-sized molecule through the gut intact. A pharmacokinetics paper on icotrokinra describes it as a synthetic macrocyclic peptide: 13 amino acids, including some non-natural ones, folded into a closed loop by a disulfide bond between two modified cysteine residues. That ring shape is the trick. A straight peptide chain is an easy target for digestive enzymes, which cut at specific points along an open strand; cyclizing the ends together removes most of those cut points and also makes the molecule more resistant to the stomach's pH swings.

It still isn't efficient. The same paper reports oral bioavailability of roughly 0.1–0.3% in animal studies — only a tiny fraction of each dose actually reaches the bloodstream, with most of it passing through and out in feces unabsorbed. Notably, icotrokinra does this without an absorption-enhancing additive; oral semaglutide, by contrast, is co-formulated with a chemical (SNAC) specifically to boost gut absorption. Low bioavailability sounds like a flaw, but it works here because the drug is extremely potent at its receptor — it needs only a small fraction of each dose to get through.

What's known and what isn't

The trial itself has real strengths: it's randomized, it's large enough (255 of 311 enrolled patients, or 82%, completed all 112 weeks) to support the headline numbers, and the two-year follow-through is unusually long for a dermatology drug trial. It's also industry-run — Johnson & Johnson sponsored ICONIC-TOTAL, and the reporting on it credits company employees as co-authors alongside outside physicians, which doesn't invalidate the data but is worth knowing when reading a press release instead of the eventual peer-reviewed paper.

The bigger caveat is about what the two-year number actually measures. Everyone on placebo switched to icotrokinra at week 16, so beyond that point there's no concurrent placebo group left to compare against — the week 112 figures describe how a self-selected group of continuing responders did over time, not how icotrokinra performs against no treatment at two years. The 18% who didn't make it to week 112 are also a gap: the release doesn't say how many dropped out for lack of effect versus for unrelated reasons. None of that undercuts the headline finding that an oral peptide can match injectable-biologic-level skin clearance — the open question is durability against a real comparator, not just against itself. For a sense of how uneven the human evidence base is across peptide research generally, our earlier look at a UCLA review of 565 peptide studies is a useful baseline — most peptide claims never make it as far as a two-year, 311-person, FDA-approved trial at all.

What this means for researchers

Icotrokinra is a proof of concept more than a universal fix: its macrocyclic, protease-resistant design is specific to this molecule and this receptor, and the sub-1% bioavailability that works for a highly potent IL-23 blocker would likely fail for a less potent target. But it demonstrates that oral delivery of a receptor-blocking peptide is achievable outside the metabolic-disease space where oral peptide formulation work has concentrated (oral semaglutide being the best-known example), which is relevant to anyone tracking delivery technology for other receptor-targeted peptides in development.

It also reframes what "durable" evidence looks like for this drug class. A two-year, randomized, multi-site dataset with pre-specified endpoints is a meaningfully higher evidentiary bar than the single-arm, short-duration study designs that dominate peptide research more broadly. Whether that durability holds up against an active comparator, and whether the formulation chemistry generalizes beyond IL-23, are the two threads worth following as more data accumulates.

One wry footnote: all that molecular engineering to survive the gut, and the pharmacokinetics paper still reports that well over 99% of each dose never makes it into the bloodstream at all — the designers built a peptide tough enough to survive digestion mostly so it could keep traveling through unabsorbed.